DK1313762T3 - Suppressor-gen - Google Patents

Suppressor-gen

Info

Publication number
DK1313762T3
DK1313762T3 DK01954168T DK01954168T DK1313762T3 DK 1313762 T3 DK1313762 T3 DK 1313762T3 DK 01954168 T DK01954168 T DK 01954168T DK 01954168 T DK01954168 T DK 01954168T DK 1313762 T3 DK1313762 T3 DK 1313762T3
Authority
DK
Denmark
Prior art keywords
suppressor gene
modulating
activity
tumour suppressor
polypeptides capable
Prior art date
Application number
DK01954168T
Other languages
Danish (da)
English (en)
Inventor
Xin Lu
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019018A external-priority patent/GB0019018D0/en
Priority claimed from GB0029996A external-priority patent/GB0029996D0/en
Priority claimed from GB0112890A external-priority patent/GB0112890D0/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK1313762T3 publication Critical patent/DK1313762T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
  • Bipolar Transistors (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK01954168T 2000-08-04 2001-08-06 Suppressor-gen DK1313762T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0019018A GB0019018D0 (en) 2000-08-04 2000-08-04 Suppressor gene
GB0029996A GB0029996D0 (en) 2000-12-08 2000-12-08 Suppressor gene
GB0112890A GB0112890D0 (en) 2001-05-26 2001-05-26 Suppressor Gene

Publications (1)

Publication Number Publication Date
DK1313762T3 true DK1313762T3 (da) 2006-10-30

Family

ID=27255828

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01954168T DK1313762T3 (da) 2000-08-04 2001-08-06 Suppressor-gen

Country Status (14)

Country Link
US (1) US20040053262A1 (pt)
EP (2) EP1710582A3 (pt)
JP (1) JP2004525605A (pt)
CN (1) CN1310942C (pt)
AT (1) ATE332309T1 (pt)
AU (2) AU2001276515B2 (pt)
CA (1) CA2417368A1 (pt)
CY (1) CY1106187T1 (pt)
DE (1) DE60121346T8 (pt)
DK (1) DK1313762T3 (pt)
ES (1) ES2269430T3 (pt)
HK (1) HK1057377A1 (pt)
PT (1) PT1313762E (pt)
WO (1) WO2002012325A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852108B2 (en) 2002-05-14 2005-02-08 Spiration, Inc. Apparatus and method for resecting and removing selected body tissue from a site inside a patient
AU2003299132A1 (en) 2002-10-07 2004-04-23 Genome Research Limited P53 binding polypeptide
GB0223187D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Screen
EP1690094A1 (en) * 2003-12-04 2006-08-16 Ludwig Institute For Cancer Research Screening assay and treatment
EP1697751A2 (en) * 2003-12-04 2006-09-06 Ludwig Institute For Cancer Research Assay and treatment
GB0328690D0 (en) * 2003-12-10 2004-01-14 Ludwig Inst Cancer Res Tumour suppressor protein
EP1725678A1 (en) * 2004-03-12 2006-11-29 Ludwig Institute For Cancer Research Differential drug sensitivity
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
EP2270512B1 (en) * 2004-12-08 2016-03-23 Cedars-Sinai Medical Center Methods for diagnosis of Crohn's disease
PL1838350T3 (pl) * 2005-01-20 2015-02-27 Ryboquin Company Ltd Modulatory aktywności ubikwitynazy itch
WO2008045344A2 (en) * 2006-10-06 2008-04-17 The General Hospital Corporation Methods to determine responsiveness to cisplatin treatment
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
EP2475378B1 (en) * 2009-09-10 2019-07-24 Mayo Foundation For Medical Education And Research USP10 modulation for use in the treatment of cancer
WO2013131019A1 (en) 2012-03-02 2013-09-06 Ludwig Institute For Cancer Research Ltd. Iaspp phosphorylation and metastatic potential
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CN116218970A (zh) 2015-11-19 2023-06-06 赛纳生物科技(北京)有限公司 用于获得和校正目标多核苷酸的序列信息的方法
CN106874709B (zh) * 2015-12-12 2019-03-01 北京大学 测序结果中序列数据错误的检测和校正方法
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
WO2000020587A2 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US7141384B1 (en) * 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
EP1146054A4 (en) * 1998-12-03 2003-08-06 Ono Pharmaceutical Co RE1A BINDING INHIBITOR, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAID BINDING INHIBITOR
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
DE60121346D1 (en) 2006-08-17
CA2417368A1 (en) 2002-02-14
CN1446228A (zh) 2003-10-01
CN1310942C (zh) 2007-04-18
AU7651501A (en) 2002-02-18
ATE332309T1 (de) 2006-07-15
AU2001276515B2 (en) 2006-10-12
EP1313762B1 (en) 2006-07-05
HK1057377A1 (en) 2004-04-02
US20040053262A1 (en) 2004-03-18
CY1106187T1 (el) 2011-06-08
PT1313762E (pt) 2006-11-30
DE60121346T2 (de) 2007-07-19
DE60121346T8 (de) 2007-12-13
EP1313762A2 (en) 2003-05-28
JP2004525605A (ja) 2004-08-26
WO2002012325A2 (en) 2002-02-14
EP1710582A2 (en) 2006-10-11
EP1710582A3 (en) 2006-11-02
WO2002012325A3 (en) 2003-03-06
ES2269430T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
ATE332309T1 (de) Suppressor-gen
ATE370232T1 (de) Anti-apo-2 antikörper
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
DE69432031D1 (de) Huntingtin-DNA, Protein und Verwendung
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
DK1521831T3 (da) Transgent dyr der udtrykker trunkeret alzheimers tauprotein
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DE69424209T2 (de) Tumorsuppressor-Gen Merlin und dessen Verwendungen
PT816504E (pt) Acetil-hidrolase para o factor activador das plaquetas, e seu gene
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
EA199900794A1 (ru) Cash (гомолог каспазы) с "гибель-эффекторным" доменом, модуляторы функций fas-рецепторов
WO2002093127A3 (en) Methods and reagents for identifying insulin response modulators and therapeutic uses therefor
ATE344802T1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE50105756D1 (de) Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/neu-Gens
DE69839150D1 (de) Intrazelluläre glukocortikoid-induzierte leucin-zipper modulatoren von mechanismen des apoptotischen zelltodes
WO2003087832A3 (en) Diagnosis of carcinoma using raigi polypeptides
WO2002077190A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2001066745A3 (en) Presenilin/crk binding polypeptides (pcbp) and methods of use thereof
ATE257862T1 (de) Verwendung von calculus
WO2002077220A3 (en) Nucleic acids encoding human est1 proteins
WO2002093128A3 (en) Identifying insulin response modulators and therapeutic uses thereof